1351762-06-5

Basic information

• Product Name: (2-Chloro-5-Methoxy-pyriMidin-4-yl)-Methyl-aMine
• Synonyms: (2-Chloro-5-Methoxy-pyriMidin-4-yl)-Methyl-aMine;(2-Chloro-5-MethoxypyriMidin-4-yl)MethanaMine;2-chloro-5-methoxy-N-methylpyrimidin-4-amine
• CAS NO: 1351762-06-5
• Molecular Formula: C₆H₈ClN₃O
• Molecular Weight: 173.60022
• Mol File: 1351762-06-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-Chloro-5-Methoxy-pyriMidin-4-yl)-Methyl-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Chloro-5-Methoxy-pyriMidin-4-yl)-Methyl-aMine(1351762-06-5)
• EPA Substance Registry System: (2-Chloro-5-Methoxy-pyriMidin-4-yl)-Methyl-aMine(1351762-06-5)

Safety Data

• Hazardous Substances Data: 1351762-06-5(Hazardous Substances Data)

Usage

General Description

The chemical (2-Chloro-5-Methoxy-pyriMidin-4-yl)-Methyl-aMine, also known as CMMA, is a derivative of pyrimidine and amines. It is a nitrogen-containing compound with a chloro and methoxy group in its structure. CMMA is commonly used in pharmaceutical research as a building block for the synthesis of various drugs and biologically active compounds. Its structure and properties make it a versatile intermediate in organic synthesis, and it is often used as a precursor in the production of pharmaceuticals, agrochemicals, and other fine chemicals. Additionally, CMMA may exhibit biological activity of its own, making it a subject of interest in medicinal chemistry research.

Upstream product

• 74-89-5 methylamine 
• 19646-07-2 2,4-dichloro-5-methoxypyrimidine 

Relevant articles and documents

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.